Browsing Tag
SGR-1505
2 posts
Schrödinger (NASDAQ: SDGR) trims 2025 software growth forecast to 8%–13% despite strong Q3 results
Find out why Schrödinger’s revised software guidance may mark a shift in pharma AI strategy, with delayed deals and a pivot to operational efficiency.
Schrödinger earns FDA Fast Track for SGR-1505 in Waldenström macroglobulinemia amid rising therapeutic demand
Schrödinger’s SGR-1505 receives FDA Fast Track designation for Waldenström macroglobulinemia, highlighting a novel MALT1-targeted approach.